Therapy resistance is still a major obstacle to successful treatment in a significant number of pediatric acute lymphoblastic leukaemia (ALL) patients. It has been previously demonstrated that children with ALL whose leukemia cells exhibit in vitro resistance to single or a combination of drugs have a significantly worse prognosis compared to patients with sensitive leukemic cells (

Ramakers-van Woerden N, et al
Leukemia
18
(3):
521
–9
2004
). Ion channels are becoming one of the potential targets for cancer therapy and putative biochemical modulators of conventional chemotherapy (
Conti M,
J Exp Ther Oncol
.
4
(2):
161
–6,
2004
). In particular, K+ channels belonging to the hERG1 family are attracting most attention, since they are over-expressed in a broad range of primary acute myeloid leukaemias (AML) as well as in both myeloid and lymphoid leukemic cell lines (
Pillozzi S, et al
Leukemia
16
:
1791
–1798,
2002
;
Smith GA, et al,
JBC
227
:
18528
–18534,
2002
). hERG1 channel expression confers a greater capacity to engraft the bone marrow and invade the bloodstream in NOD/SCID mice injected with AML cells. This fact corresponds to a greater malignancy (shorter overall survival and higher probability to relapse) in hERG1 positive AML patients (
Pillozzi S, et al
Blood
110
:
1238
–1250,
2007
). It was also recently shown that the expression of hERG1 is related to the chemosensitivity of cancer cells to vincristine, paclitaxel, and hydroxy-camptothecin (
Chen SZ, et al
Cancer Chemother Pharmacol
56
(2):
212
–20,
2005
). We studied the expression and role of hERG1 channels in various B lymphoid leukaemia cell lines and primary childhood B lymphoid leukaemia samples. It emerged that:

  • hERG1 K+ channels are expressed in both all the leukaemia cell lines and primary childhood B leukaemia samples;

  • the N-terminus deleted, herg1b isoform was preferentially expressed in both cell lines and primary samples;

  • in childhood leukaemia patients, the level of herg1b expression correlated with response to therapy.

B lymphoid leukaemia cell lines were co-cultured on human bone marrow stromal cells, a system known to enhance leukaemia cell survival and escape from drug-induced apoptosis. In these cultures, the addition of a specific hERG1 inhibitor, E4031, induced a significant apoptosis in leukaemia cells, bypassing the protective effect of the bone marrow microenvironment. We hypothesise that hERG1 channels can represent a novel molecular device regulating drug sensitivity in childhood acute leukaemia cells, and that targeting of hERG1 channels can restore a proper pro-apoptotic response to chemotherapy in resistant B lymphoid leukemic cells.

Topics:
cell culture techniques, leukemia, pediatrics, stomas, drug resistance, leukemic cells, lymphoblastic leukemia, cancer, chemotherapy regimen, acute lymphocytic leukemia

Author notes

Disclosure: No relevant conflicts of interest to declare.

2007, The American Society of Hematology
2007
Sign in via your Institution